6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Originaltext

Diese Übersetzung bewerten

Mit deinem Feedback können wir Google Übersetzer weiter verbessern

Latest Press Releases

Time	Headline
7m ago	Yapi ve Kredi Bankasi : Successful issuance of 500 million US$ perpetual Additional Tier 1 Capital Transaction
12m ago	Crown Castle Names Kris Hinson as Chief Commercial Officer and Mark Lennon as Chief Information Officer
17m ago	Hovnanian Enterprises Reports Fiscal 2026 Second Quarter Results
17m ago	LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
17m ago	KKR Sells CIRCOR Aerospace to Parker Hannifin for $2.55 Billion

About

59.06USD+0.84 +1.44%

Closed • Updated at 13:33 GMT+00:00

Market Cap$6.34B

P/E Ratio168.74

Volume1.12M

Beta1.06

RSI72.86

Gross Margin98.25%

Health TechnologyPharmaceuticals: Major

Corcept Therapeutics Incorporated — investor relations, events, news, and company updates on 6ix.

Latest News

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)

Community Chat

Ask AI